Cover Image
市場調查報告書

HIV/AIDS:開發平台分析

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232769
出版日期 內容資訊 英文 980 Pages
訂單完成後即時交付
價格
Back to Top
HIV/AIDS:開發平台分析 Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017
出版日期: 2017年12月29日 內容資訊: 英文 980 Pages
簡介

HIV是攻擊免疫系統的病毒,減弱與感染疾病和疾病作戰的體內力量。症狀有發燒、喉嚨疼痛、身體發疹、關節痛、肌肉痛、腺體肥大等。HIV感染最容易擴大的是,不使用保險套跟HIV/AIDS感染者的陰道或肛門的性交,及與感染者共用針頭,用附有HIV的外科用器具在身體上造成深度傷口,感染HIV的血液、精液或陰道的分泌物進入開放性傷口等。

本報告提供HIV / AIDS 的治療藥開發平台現狀,及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • HIV / AIDS 概要

治療藥的開發

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10002IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 15, 46, 42, 1, 4, 104, 66 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 16, 20, 55 and 62 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017 (Contd..1), H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AbbVie Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Apotex Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bionor Pharma AS, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bukwang Pharm Co Ltd, H2 2017

List of Figures

  • Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top